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Before nonanimal toxicity tests may be officially accepted by regulatory agencies, it is generally
agreed that the validity of the new methods must be demonstrated in an independent,
scientifically sound validation program. Validation has been defined as the demonstration of the
reliability and relevance of a test method for a particular purpose. This paper provides a brief
review of the development of the theoretical aspects of the validation process and updates
current thinking about objectively testing the performance of an alternative method in a validation
study. Validation of alternative methods for eye irritation testing is a specific example illustrating
important concepts. Although discussion focuses on the validation of alternative methods
intended to replace current in vivo toxicity tests, the procedures can be used to assess the
performance of alternative methods intended for other uses. Environ Health Perspect
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Introduction
The use of animals for routine toxicity
testing is now questioned by a growing seg-
ment ofsociety. The expression ofthis con-
cern is seenwith particular darity in the 6th
Amendment to the European Union
Cosmetics Directive (1). This directive
contains a provision that it will become ille-
gal to market cosmetic products in
European Union countries if they contain
ingredients or mixtures of ingredients that
have been tested in animals (to meet the
purposes of the directive) unless there are
no valid alternatives to replace the animal
tests. New test procedures are now being
developed to meet ethical concerns and to
provide improved toxicologic information.
It is critically important to determine
whether such alternative methods are valid
for use in the safetyassessment process.
Ifalternative methods are to be success-
fully incorporated into thesafetyassessment
process, it will be necessary to demonstrate
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that the new procedures can provide at
least an equivalent level of protection to
that obtained with current methods (1).
Additionally, ifdeadlines imposed by legis-
lation such as the 6th Amendment to the
European Union Cosmetics Directive are
to be met, it is important that the valida-
tion process be conducted in a manner that
efficiently and definitively characterizes the
performance ofthe alternative methods.
Important concepts in the theory of
alternative method validation outside the
area of genotoxicity testing have been dis-
cussed extensively since the late 1980s. In
1987, Scala (2) reviewed the characteristics
of a valid test with particular emphasis on
calculating the sensitivity, specificity, and
predictive value of new test methods.
Shortly thereafter, Frazier defined valida-
tion as "the process whereby the reliability
and relevance of an alternative method is
demonstrated for a particular purpose" (3).
At approximately the same time, the
Amden I Workshop further defined impor-
tant theoretical aspects related to the valida-
tion process (4). Five years later theAmden
II Workshop (5) focused on more practical
aspects ofvalidation that had been learned
during several large multicenter validation
studies that were initiated shortly after the
Amden I Workshop. The Center for
Alternatives to Animal Testing contributed
numerous important documents in this
time frame that also developed concepts
related to the validation process (6-20).
The Multicentre Evaluation of In Vitro
Cytotoxicity program also contributed sig-
nificandy to the development oftheoretical
aspects ofthevalidation process (21,22).
Validation of alternative methods has
also been ofconsiderable interest to regula-
tory authorities. Consequently, several
international organizations, regulatory
agencies, and committees have reviewed
various aspects ofvalidation and regulatory
acceptance of alternative methods. The
U.S. Interagency Regulatory Alternatives
Group, which comprises scientists from the
U.S. Food and Drug Administration, the
U.S. Environmental Protection Agency,
and the U.S. Consumer Products Safety
Commission, has examined the validation
and regulatory acceptance process (23).
This organization gave way to the U.S.
National Institute of Environmental
Health Sciences Interagency Coordinating
Committee for the Validation of Alter-
native Methods (ICCVAM), which has
completed an extensive review of the
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validation and regulatory acceptance of
alternative methods (24). The European
Commission formed the European Centre
for the Validation ofAlternative Methods
(ECVAM), which plays a leading role in
facilitating the optimization (prevalidation)
and validation of alternative methods.
ECVAM has contributed extensively to the
field ofvalidation in the form of publica-
tions on prevalidation (25), and validation
(26-36), ECVAM workshop reports on
the status of method development for a
wide range oftoxicity end points (37-61),
and ECVAM task force reports (25,62).
ECVAM has also coordinated validation
studies on eye irritation testing (63), photo
irritation (64), and skin corrosion (42).
Finally, the Organisation for Economic
Co-operation and Development (OECD)
test guidelines program has produced an
important report on the harmonization
and validation of alternative toxicological
test methods (65).
This paper summarizes some important
aspects of the validation process that have
been developed through these efforts. This
discussion focuses on thereplacement ofani-
mal tests that arecurrendy used to determine
the hazard of chemicals for regulatory
purposes. Itprovides guidance on thedesign,
execution, and evaluation ofvalidation pro-
grams. It also describes how to objectively
assess the performance of the alternative
methods relative to the in vivo test to be
replaced and discusses the factors that must
beconsideredwhen the relevance ofan alter-
native method is assessed. The concepts
presented in this review are consistent with
and expand on those developed by Frazier
(3), the Amden Workshops (4,5), the
ICCVAM (24), and OECD (65) reviews
on validation, and other recent publications
on thevalidationprocess (12,13,66).
Definition ofValidation
Validation has been defined as "the estab-
lishment of the reliability and relevance of
an alternative methodforaspecificpurpose"
(3,4). To assess the validity of an alterna-
tive method, it is important to clearly
define the terms reliability and relevance.
For a toxicologist to rely on an alternative
method, two things must be known about
its performance. First, it must be possible to
consistently reproduce the results from an
alternative method. Second, it must be
possible to consistently and correctly con-
vert the results from the alternative method
into useful predictions of toxicity so that
appropriate safety assessments can be made.
Thus, reliability may be defined as the
establishment of the reproducibility of the
dataobtained from amethod across different
laboratories and the reproducibility of the
predictions of toxic hazard after application
of a clearly stated prediction model to the
alternative method data across appropriately
definedsets oftest substances (66).
Once the reproducibilityofan alternative
method has been confirmed, then its rele-
vance must be evaluated. Relevance has
been defined as establishing the scientific
meaningfulness and usefulness of results
from an alternative method for a particular
purpose (3,4). Establishing usefulness and
meaningfulness is important because hazard
predictions obtained from scientifically
credible alternative methods have a higher
probability of being correct. To establish
relevance, all available information related
to the fundamental scientific basis, reliabil-
ity (as defined above), and practical opera-
tion of the alternative method, and to the
in vivo toxicity test to be replaced must be
thoroughly reviewed. Ultimately, a judg-
ment must be made aboutwhether or not a
method is relevant for aparticular purpose.
Prevalidation ofAlternative
Methods
A method must be sufficiently developed
before it is considered ready for evaluation
in a validation study (Figure 1) (25,66).
First, a test must have been conceived and
then developed sufficiently that it can be
conducted routinely in an appropriately
equipped laboratory by experienced techni-
cians. Second, an adequate prediction
model must be available that allows correct
interpretation ofits results (66,67). Third,
there should be evidence that an alternative
method is relevant for the intended pur-
pose. Fourth, there should be evidence that
the method can be reproduced across sev-
eral laboratories. Finally, adequate proto-
cols and standard operating procedures
(SOPs) must be available so that any par-
ticipating laboratory can conduct the assay.
Once it has been confirmed that factors are
adequate, a method may then be assessed
in avalidationstudy.
Importance ofthe
Prediction Model
For an alternative method to be useful for
making safety assessments, it must be pos-
sible to translate the results into correct
predictions of in vivo toxicity. This is usu-
ally done by applying algorithm(s) to the
alternative method data that convert them
into toxicity predictions. Because such
algorithms constitute models that allow the
prediction of toxicity, they have been
called prediction models (66). If an alter-
native method does not have an adequate
prediction model, it cannot be used in the
safety assessment process. It is therefore
essential that validation programs test the
utility of the prediction model associated
with each alternative method evaluated. In
fact, ifthe prediction model is not defined
prior to the start of a study, its validity
cannot be assessed (67).
An adequate prediction model must
have at least four components (66). First,
there must be a clear definition of every
type of data available from the alternative
method. Second, the prediction model
must provide an algorithm that allows an
individual to convert each data type into a
prediction ofthe in vivoend point ofinter-
est. Third, the prediction model should
provide an indication of the accuracy and
the precision ofthe predictions. For exam-
ple, the 95% confidence intervals (CI) for a
given prediction (95% CIpred) may be pro-
vided. Finally, the prediction model must
define the test substances for which the
method is valid, limitations on the use of
the method, and the specific purpose for
which the test is to be used.
Practical experience has shown the
benefits in having a prediction model
clearly defined before a validation study
starts. First, it provides a clear picture ofthe
results that should be expected at the end of
a validation study if the method is valid.
This allows the reviewers of a validation
study to objectively assess the performance
of the method at the end of the study.
Second, if the prediction model is defined
at the start, it is possible to work with stat-
isticians to design the validation study in
an efficient and proper way. Data-based
methods can be used to determine the
appropriate number of test substances and
laboratories to indude in astudyin order to
adequately assess a method's performance.
Assessing the Reliability
of an Alternative Method
in a Validation Study
The first step in assessing the validity ofan
alternative method is to conduct a study
designed to measure reliability. To conduct
a validation study, there are several impor-
tant steps that must be completed (Figure
1). The study must be designed, the partici-
pating laboratories must be identified and
recruited, a reference set oftest substances
must be assembled and distributed under
code, the qualityofthe in vivodatamust be
assessed, and each test substance must be
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Figure 1. The validation of an alternative method. The flow chart depicts one of several possible approaches that
may be used as guides to design and conduct a validation program. The steps on the left side of the chart repre-
sent the validation process. The pathwaywithin the shaded box represents the validation study process. The right
side ofthe chartdepicts the steps associated with improving the performance ofthe alternative method and defin-
ing another prediction model prior to inclusion of the method in a subsequent validation study. Any new method,
whether based on a fundamental understanding of toxic mechanisms or on empirical correlations, may be
assessed forvalidity using this approach. From Bruner etal. (66).
evaluated in the alternative method (66).
Ideally, all data supporting the validity of
the test method should be obtained and
reported in accordance with Good Lab-
oratory Practices (24,65). Then, when the
alternative method data are available, the
prediction model defined before the start of
the study must be used to predict the in
vivo toxicity of each test substance. If the
toxicity predictions are similar to the actual
toxicity of the test substances, and if the
same results were obtained across all ofthe
participating laboratories, it would provide
evidence that the method is reliable. If,
however, the toxicity is not predicted
correctly, or if the results are not similar
across the participating laboratories, it
would not be possible to consider the
method is reliable. Ifthe alternative method
is found not reliable, it may be optimized, a
new prediction model developed, and then
the new method tested in a subsequentvali-
dation study. Alternatively, the method
may be abandoned if additional work is
unlikelyto be fruitful (Figure 1).
Assessing the Relevance
of an Alternative Method
As noted above, an alternative method may
be considered relevant when it is shown
that the predictions oftoxicity obtained are
meaningful and useful for a specific pur-
pose. Establishing relevance is a judgmen-
tal process requiring evaluation of all
available supporting data and scientific evi-
dence supporting the use of an alternative
method. This involves evaluation of key
performance benchmarks that provide a
useful context for interpreting the results
obtained from a validation study, the
mechanistic basis for the test, and other
factors related to the performance of the
method (66).
Establishment ofKeyPerformance
Benchmarks
Theoretical Best Performance. One
criterion used for assessing relevance is to
estimate the theoretical best performance
expected from the alternative method.
Ideally, there should be a high correlation
coefficient in the relationship between the in
vivo and alternative method data, and a nar-
row 95% CIpred. However, there are certain
technical limitations associated with alterna-
tive methods that decrease the likelihood
that such performance will be observed. If
this is true, the question that must be asked
is, What level ofperformance is possible and
reasonable? Computer simulations may be
used to provide guidance on answering this
question (66). The results from ahypotheti-
cal eye irritation alternative method valida-
tion study provide an example ofhow this
maybe accomplished. Let us assume that the
relationship between the maximum average
score (MAS) from the Draize eye irritation
test,y, and an alternative method result, x, is
definedbythefollowing equation:
y= 1.1(x),
where the alternative method scores, x,
range between 0 and 100. In this case the
predicted MAS will range between 0 and
110, which is consistentwith the Draize eye
irritation test scoringscheme (68). The sim-
ulation may be run many times (10,000 in
this example). Each run of the simulation
produces a corresponding value ofy, which
is apredicted MAS. Simulations mayalso be
conducted with scores for x restricted to a
range between 0 and40, which is about half
ofthe eye irritation scale. This can be done
to simulate expected results from studies
that use a reference set oftest substances in
the least irritating halfofthe Draize eye irri-
tation scale as would occur with more mild
testsubstances.
Ifa low level ofvariability is assumed in
both in vivo and alternative method data,
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the Pearson's correlation coefficient is high
for both the full range ofeye irritancy and
for the least irritating part ofthe eye irrita-
tion scale (Figure 2, Table 1). However, in
vivo and alternative method data can show
considerable variability. Experience shows
that the coefficient of variation (CV) is
approximately 10 to 30% for typical alter-
native methods (66). The CV for the
Draize eye irritation test ranges between 40
and 60%. Accordingly, computer simula-
tions conducted with the CV for the alter-
native method and the in vivodata set at 20
and 40%, respectively, show that the
expected correlation coefficients will be
approximately 0.86 for the full set of test
materials, and approximately 0.7 for the
least irritating portion or the Draize eye
irritation scale (Figure 2, Table 1). The
results of these simulations also indicate
that the 95% CIpred for apredicted MAS of
55 is relatively wide at ±35.2 (Table 2).
Thus, if an alternative method using the
algorithm, y = 1.1x, produces a correlation
between the alternative method data and in
vivodataofapproximately 0.7 to 0.8 with a
95% Clpred in the range of ±35, it would
provide evidence supporting its relevance as
a replacement for the in vivo test.
Comparison with the Performance of
theinVivo Testto BeReplaced Asecond
A
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performance benchmark used to judge the something about the performance of the
relevance of an alternative method is to in vivo test. Returning to the example of
compare its performance characteristics the Draize eye irritation test, computer
with the performance characteristics ofthe simulations show that the Pearson's corre-
in vivo test that will be replaced. To make lation coefficient between two sets of
such a comparison, it is necessary to know Draize eye irritation test data on the same
Table 1. Expected Pearson's correlation coefficients when the error in in vivo and alternative method data are
considered.
Imposed coefficientofvariation Expected Pearson's correlation coefficient
Alternative method In vivo Full range, x=1-100 Restricted range, x=1-40
Ideal conditions
0.05 0.05 0.994 0.990
0.1 0.1 0.975 0.960
Typical conditions
0.2 0.4 0.860 0.719
0.2 0.5 0.828 0.652
0.2 0.6 0.803 0.608
Computer simulations were used to assess the effects of variability in eye irritation test and alternative method
data on the correlation coefficients expected between the data sets. The model used in the simulation assumed
that the algorithm y=(1.1)xdescribes the relationship between the in vivoand alternative method data. Valuesfor
x=0-100 were used to simulate responses across the entire Draize eye irritation scale. The simulations were con-
ducted with test substances having the full range of response (x=1-100) and for a restricted range representing
the least irritating part of the eye irritation scale (x=1-40). Each result is based on 10,000 runs of the simulation.
Results are shown for the simulations where the variability is set relatively low (ideal conditions), and where the
variability was setata level consistent with performance ofcurrently available alternative methods and the in vivo
test (practical conditions). Additionally, simulations were conducted where the variability was set at zero for the
alternative method (theoretical bestconditions) and where the variability ofthe altemative method was setequiv-
alent to the eye irritation test (alternative method equivalent to in vivo). The results of these simulations demon-
strate thatvariability in the data sets can have a significant effect on the performance ofthe alternative method in
predicting the in vivoresponse. Thus, the effect ofvariability must be taken into accountwhen the performance of
an alternative method is assessed.
B
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Figure 2. Effects ofvariability in the Draize test and alternative methods on correlation. Computer simulations were used to assess the effects of variability in the eye irrita-
tion test; alternative method data onthe relationship between the two data sets is illustrated. The model used in the simulation assumed thatthe algorith, y=(1.1)xdescribes
the relationship between the in vivo(MAS) and alternative method data. Values for x=0-100 were used to simulate responses across the entire Draize eye irritation scale.
Different levels ofvariability were added to the alternative method and in vivoscores in each run ofthe simulation. The xand yvalues generated in 1000 runs ofthe simula-
tion are plotted on the figures. (A): The expected relationship between the MAS and the alternative method results when the variability is relatively low. In this case, the CVs
applied to both the in vivoand alternative method data were 5%. (B): The expected relationship between the maximum average scores and alternative method results under
typical conditions. The CVsapplied tothe in vivoand alternative method data were 50 and 20%, respectively.
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test substances will be approximately 0.87 if
the in vivo CV=40% (Figure 3). The 95%
CIpred in this case will be approximately
±35 for a predicted MAS of 55 (Table 2).
Table 2. 95% Confidence interval for predicting an in
vivoeye irritation score (95% CIpred)when the predicted
maximum average score is 55.
Imposed coefficient ofvariation
Alternative method In vivo 95%Clpred
Alternative method
predicting In vivo
0.2 0.4 ±35.2
0.2 0.5 ±40.2
0.2 0.6 ±45.6
Draize predicting
Draize
0.4 ±34.8
0.5 ±43.2
0.6 ±50.6
Computer simulations were used to assess the effects
of variability in eye irritation test and alternative
method data on the 95% Cipred. For predictions of in
vivo scores from an alternative method result, the
model used in the simulation assumed that the algo-
rithm, y=(1.1)x, describes the relationship between
the in vivo and alternative method data. Values for
x=0-100 were used to simulate responses across the
entire Draize eye irritation scale. For predictions of in
vivo scores from the in vivo result, the model used in
the simulation assumed that the algorithm, y=x,
describes the relationship between the two sets of
data. Each result is based on 10,000 runs of the simu-
lation. The coefficient of variation (CV) for the alterna-
tive method was set at 20%. The CV used for the in
vivo data ranged from 40-60% which is consistent
with reports inthe scientific literature (69).
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Figure 3. Effects of variability on the capacity of the
Draize test to predict its own result. Computer simula-
tions were used to assess the effects of variability in
the capacity of the Draize eye irritation test to predict
its own result. The model used in the simulation
assumed that the algorithm y=x describes the rela-
tionship between the in vivo data sets (MAS). Values
for x=0-110 were used to simulate responses across
the entire Draize eye irritation scale. The x and yval-
ues generated in 1000 runs of the simulation are plot-
ted on the figure. The expected relationship between
an actual MAS and a predicted MAS when the CV
applied is 40% as illustrated.
If the predictive capacity of the alternative
method is similar to or better than these
values, itwould support the relevance ofthe
alternative method.
Other Factors Supporting the
Relevance ofan Alternative Method. In
addition to these performance benchmarks,
it is important to consider other factors
supporting the relevance of an alternative
method (66). First, the mechanistic basis of
the new assay should be understood (9). A
stronger mechanistic understanding
increases confidence that the predictions
from the alternative method will be correct.
Second, it is important to define the known
limitations in the use of an alternative
method. For example, a new procedure
may be valid for only a small number of
substances relative to the universe ofmate-
rials that must be tested. If the method is
limited in its application, it may not be very
relevant for general use in the safety assess-
ment process. Third, the technical limita-
tions of an alternative method must be
known. An assay that can handle all types
of test substances may ultimately be more
relevant for general use than one restricted
to only one type (e.g., water-soluble test
materials). Finally, performance of the
alternative method reported in the scientific
literature should also be considered.
Once this information has been
assembled and evaluated, the overall rele-
vance of the method for its defined pur-
pose must be assessed. If the conclusion is
that the alternative method is not relevant,
the test cannot be considered valid, and it
is necessary to consider whether there is
value in optimizing the assay, developing a
new prediction model, and assessing it in a
subsequent validation study (Figure 1).
Conversely, if the data support its rele-
vance, that would suggest the alternative
method may be used in the safety assess-
ment process and should be considered for
official acceptance by regulatory authorities
(Figure 1). To gain regulatory acceptance,
regulatory authorities and independent
reviewers should receive all data supporting
the conclusions obatined from the program
so that the results and conclusions can be
given a complete peer review (24).
Publication of results in a high-quality,
peer-reviewed journal provides additional
credibility to the conclusions obtained
from astudy (24).
Conclusion
The reliability and relevance ofan alternative
method for a specific purpose are estab-
lished during the validation process. The
validation study, a part of the overall
validation process, should be considered a
confirmation step that provides quantita-
tive evidence that an alternative method is
reliable. To efficiently assess the reliability
of an alternative method, a prediction
model must be defined before the com-
mencement ofthestudy. The assessment of
relevance requires a thorough review ofall
the performance data and other supporting
information related to both the alternative
method and the in vivo test it will replace.
Ultimately, those participating in the vali-
dation process must integrate this infor-
mation and render a judgment on whether
the method, when used for a specifically
defined purpose, is useful andmeaningful.
The importance oftheprediction model
has been stressed because the primary pur-
pose of an alternative method is to provide
predictions oftoxicity that will be used by
toxicologists to make decisions during the
safety assessment process. Because the pre-
diction of toxicity is the critical piece of
information needed from an alternative
method, it is important that the procedures
used to arrive at these predictions be vali-
dated during the validation process.
Previous discussions ofvalidation have indi-
rectly addressed the need for the prediction
model, but have focused on the identifica-
tion of such models after the validation
study is completed (4,5) However, if an
adequate prediction model is defined at the
beginning of a validation study, it allows
those evaluating an alternative method to
construct a clear picture ofwhat the results
from a valid assay will look like before the
study begins. When the results from the
validation study become available, objective
comparisons can be made between the pre-
defined picture provided in the prediction
model and the actual study results. Such an
approach has an advantage in that it makes
validation a confirmatory process and mini-
mizes post hoc data fitting that does not
provide definitive answers on alternative
method performance. The value ofdefining
the prediction model prior to the start of a
validation studyhas been demonstrated in a
recently completed eye irritation test
methodvalidation program (70).
In addition to facilitating objective
assessment of the predictive capacity of an
alternative method, the prediction model is
also an important tool that can be used to
guide the design of a validation study.
When the models used for making the pre-
dictions are stated at the beginning ofavali-
dation study, statisticians can use the
information to provide data-based advice on
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such things as the numbers oftest substances
to be included in the reference set of test
substances, the number ofparticipating lab-
oratories needed, and the range of toxicity
needed to adequately assess alternative
method performance. Thus, the incorpora-
tion ofthe prediction models into the vali-
dation process at the beginning not only
improves a reviewer's ability to assess the
validity ofan alternative method, but also
has the potential to decrease the cost and
time required to validate an alternative
method by facilitating better study design.
This is particularly important given thehigh
costs oflarge, multicentervalidation studies.
The computer simulations on the
Draize eye irritation test provide a striking
view of the results that can be expected
from a validation study if the level of
uncertainty in the data from the reference
test to be replaced is high. In such cases, it
will not be possible to demonstrate that
alternative methods provide predictions
that have high levels ofcertainty. As noted
earlier, one of the most important factors
to consider in the design of a validation
study is to assure that the quality of data
used for comparisons against the alterna-
tive method results are as high as possible.
It has become apparent that obtaining test
substances with high quality in vivo data is
a difficult problem that must be overcome
if rapid progress in the development and
validation of alternatives is to be made.
The simulations also demonstrate why it is
important to establish objective criteria to
be used as the basis for judging alternative
method performance. The establishment of
data-based performance benchmarks will
better guide reviewers ofa validation study
in setting realistic performance expecta-
tions given the real-world technical limita-
tions characteristic of the current state of
the art (69,71,72).
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